REDUCING LOW-VALUE CARE IN A POST-PANDEMIC WORLD

MARK FENDRICK

DIRECTOR

CENTER FOR VALUE-BASED

INSURANCE DESIGN








HAIL TO THE FRONTLINE

So many selfless people are doing truly wonderful things to successfully defeat this pandemic.

THANK YOU.

HEALTH CARE COSTS ARE A TOP ISSUE FOR PURCHASERS AND POLICYMAKERS

Solutions Must Protect Consumers, Reward Providers and Preserve Innovation



Policy deliberations focus primarily on alternative payment and pricing models Moving from a volume-driven to value-based system requires a change in both how we pay for care and how we engage consumers to seek care




A SECOND HEALTH CARE PANDEMIC WILL FOLLOW COVID-19

WE NEED TO PLAN
ACCORDINGLY











Patient Rushed Into Unnecessary Surgery To Save Cash-Strapped Hospital bit.ly/314r3zN




CRISIS INTO OPPORTUNITY: CAN COVID-19 HELP SET A PATH TO IMPROVED HEALTH CARE EFFICIENCY?



Indicated cancer screenings

(actual data)





CRISIS INTO OPPORTUNITY: CAN COVID-19 HELP SET A PATH TO IMPROVED HEALTH CARE EFFICIENCY?

Build on existing alternative payment models that base reimbursement on patientcentered outcomes, increase reimbursement for high-value services and reduce or cease payment for known low-value care

Leverage the widespread adoption of electronic health records (EHRs) to make it easier to order high-value care with simplified processes and discourage the use of low-value care with alerts

Align patient cost-sharing with the value of the underlying services; reduce out-of-pocket cost on high value services and increase patient cost on low-value care





Paying for More Generous Coverage of High-Value Care:

Reduce Spending on Low-Value Care



LOW-VALUE CARE

A silver lining to COVID-19: Fewer low-value elective procedures



PAYING FOR MORE GENEROUS COVERAGE OF HIGH VALUE CARE:

REDUCE SPENDING ON LOW VALUE CARE

Increase premiums – politically not feasible

Raise deductibles and copayments - 'tax on the sick'

Reduce spending on low value care

Low-value care (LVC) costs stakeholders more than \$340 billion annually while offering little to no patient benefit

Examples include:



Vitamin D screening tests

Diagnostic tests before low-risk surgery





PSA screening for men 70 and older

Branded drugs when identical generics are available





Low-back pain imaging within 6 weeks of onset

WASTE IN THE MEDICARE PROGRAM: A NATIONAL CROSS-SECTIONAL ANALYSIS OF 2017 LOW-VALUE SERVICE USE AND SPENDING

- Medicare fee-for-service claims for beneficiaries enrolled for two years
- 35 low-value service measures reflecting Choosing Wisely® recommendations and other guidelines using the Milliman MedInsight® Health Waste Calculator
- Low-value services were common and costly in Medicare. Over one-third of beneficiaries received at least one low-value service
- Three services comprised half of wasteful spending: opioids for acute low back pain (\$188 million, 26.0%), concurrent use of two or more antipsychotic medications (\$94 million, 13.0%), and unnecessary colorectal cancer screening (\$79 million, 11.0%) suggesting targeted opportunities for waste reduction.



Utilization and Spending on Low-Value Medical Care Across Four States





Table 1. Claims Data Sources included in APCD, by State

	Commercial	Medicaid	Medicare FFS	Medicare Advantage	Patient <i>and</i> Plan Spending
Maine	×	×	×	×	×
Washington	×	×			
Colorado	×	×	×	×	×
Virginia	×	X	X		X




Total Spending on 47 Low-Value Services by Four States in Medicaid and Commercial Plans, 2015-2017

Total and PMPM Waste Spending Across Four States and Three Years



Notes: this figure shows total spending (sum of plan and patient spending) on the 47 low-value services for commercial and Medicaid only, across three years for all four states: Colorado, Maine, Virginia, Washington.

Spending on 47 Low-Value Services in Medicaid and Commercial Plans in 2017 by Patients and Plans



Notes: spending in thousands \$. These figures only represent Maine, Colorado, and Virginia. Washington did not separately report patient and plan spending.



Spending on "Top 10" Commercial and Medicaid Low-Value Services by Volume in 2017

Table 4. Low-Value Spending on Top 10 services by Volume, in 2017

2017	Total Spend on "Top 10" LVC Services	PMPM	% Total Medicaid a Commercial Waste Sr	
Maine	\$49,659	\$6.67		78%
Washington*	\$278,236	\$8.69		80%
Colorado	\$160,125	\$5.65		73%
Virginia	\$179,322	\$4.37		68%
Total	\$667,343	\$6.13		70%

Notes: total spending in thousands \$. PMPM = total spending on the top 10 services divided by total member months (Appendix 3) provided by the states for 2017. These data only include Medicaid and commercial spending. *Washington did not separately report patient and plan spending, and estimated total spending based on standard pricing for Medicaid and commercial plans.

Total Plan and Patient LVC Spending, including Medicare, 2017

	Total LVC Spending, with Medicare	PMPM, with Medicare	% Total Health Spending, with Medicare
Maine	\$146,884	\$12.53	1.72%
Colorado	\$358,111	\$9.67	1.86%
Virginia	\$627,768	\$10.66	1.92%

Maine and Colorado include Medicare FFS and Medicare Advantage, Virginia Medicare FFS only



The effect of increased cost-sharing on low-value service use

```
Jonathan Gruber<sup>1</sup> | Johanna Catherine Maclean<sup>2</sup> | Bill Wright<sup>3</sup> | Eric Wilkinson<sup>4</sup> | Kevin G. Volpp<sup>5</sup>
```

- Examined the effect of a value-based insurance design (VBID) program implemented at a large public employer in the state of Oregon
- The program substantially increased cost-sharing for several healthcare services likely to be of low value for most patients: diagnostic services (e.g., imaging services) and surgeries (e.g., spinal surgeries for pain).
- Findings suggest that the VBID significantly reduced the use of targeted services




V-BID X

Expanding Coverage of Essential Clinical Care Without Increasing Premiums or Deductibles



V-BID X: EXPANDING COVERAGE OF ESSENTIAL CLINICAL CARE WITHOUT INCREASING PREMIUMS OR DEDUCTIBLES

Clinically driven plan designs, like V-BID X, reduce spending on low-value care



...creating headroom to reallocate spending to high-value services without increasing premiums or deductibles

High-Value Services and Drugs with Highly Reduced or Eliminated Cost-Sharing

Glucometers and testing strips	Anti- thrombotic/anticoagulants	
LDL testing (hyperlipidemia)	Anti-depressants	
Hemoglobin A1C testing (diabetes)	Statins	
Cardiac rehabilitation	Antipsychotics	
INR Testing (hypercoagulability)	ACE inhibitors and ARBs	
Pulmonary rehabilitation	Beta blockers	
Peak flow meters (asthma)	Buprenorphine-naloxone	
Blood pressure monitors (hypertension)	Anti-resorptive therapy	
Glucose lowering agents	Tobacco cessation treatments	
Rheumatoid arthritis medications	Naloxone	
Inhaled Corticosteroids	Thyroid-related	
Antiretrovirals		

High-Value Branded Drug Classes with Reduced Cost Sharing

Pre-exposure prophylaxis for HIV

Hepatitis C directing-acting combination

Anti-TNF



Low-Value Services with No Coverage

Spinal fusions

Vertebroplasty and kyphoplasty

Vitamin D testing

Proton beam therapy for prostate cancer



HHS 2021 PAYMENT RULE STRONGLY ENDORSES V-BID X

6. Promoting Value-Based Insurance Design

Borrowing from work provided by the Center for Value-based Insurance Design at the University of Michigan ¹⁵⁶ (the Center), Table 5 lists high value services and drugs that an issuer may want to consider offering with lower or zero cost sharing. Table 5 also includes a list of low value services that issuers should consider setting at higher consumer cost sharing. High value services are those



V-BID X:

KEY TAKEAWAYS

Cost neutral V-BID designs are feasible. Coverage can be enhanced for targeted high-value services, without raising premiums and deductibles

There are a large number of plausible combinations of services or cost-sharing changes that could fit different needs and goals, depending on the carrier and market

MULTI-STAKEHOLDER EFFORTS TO REDUCE LOW-VALUE CARE: SMARTER CARE VIRGINIA



CLINICAL LEARNING COMMUNITY

Six health systems and 3 clinically integrated networks working together to reduce seven provider-driven measures.



EMPLOYER TASK FORCE

16 Virginia employers working together to increase their knowledge of low-value care and identify consumer-driven measures to drive change through benefit design and employee education.



PLAN TO IMPROVE HEALTH VALUE

Developed at a joint conference of the clinical learning community and employer task force members.



ENHANCING ACCESS AND AFFORDABILITY TO ESSENTIAL CLINICAL SERVICES: A NEED TO REDUCE LOW VALUE CARE IN THE 'NEW NORMAL'

Expand pre-deductible coverage/reduce consumer cost-sharing on high-value clinical COVID-19 related care and other essential chronic disease services

Implement clinically-driven plan payment reform, technologies and benefit designs that increase use of high-value services and deter low value care

Identify, measure and reduce low-value care to pay for more generous coverage of high-value care

STAY SAFE. STAY HEALTHY. STAY CONNECTED.



vbidcenter.org/ smarterhc.org/



<u>@UM_VBID</u> <u>@SmarterHC</u>



vbidcenter@umich.edu info@smarterhc.org



IN PARTNERSHIP WITH

